Sclerosteosis is a rare autosomal recessive bone disorder marked by excessive bone growth of the skull and tubular bones. Up to now, research showed: sclerosteosis was caused by loss-of-function mutations in the SOST gene, encoding sclerostin.
Recently, researchers within the european SYBIL consortium identified disease causing mutations in LRP4, a binding partner of sclerostin, in three Sclerosteosis patients. Upon binding to sclerostin, LRP4 can inhibit the canonical WNT signaling which is known to be an important pathway in the regulation of bone formation.
A Lrp4 mutated sclerosteosis knock-in mouse model generated by PolyGene showed to be a good model for the human sclerosteosis phenotype. This model will be used for further investigation of the LRP4 regulating bone formation mechanism.
This work was published in the Journal of Bone and Mineral Research on May 6th 2017 by the group of Prof. Wim van Val located at the Center of Medical Genetics at the University of Antwerp in Belgium.
>> Online Publication
Every year, ECTS creates a platform for researchers and clinicians working in the musculoskeletal field to strengthen collaborations and discuss the latest advances.
PolyGene brings great expertise in developing relevant in vivo models of rare skeletal and common skeletal diseases to many european research institutes (e.g. within the EU-funded SYBIL program).
The next PolyGene Seminar will take place June 1th at the Swiss institute for regenerative medicine (SIRM) in Taverne – Torricella, Switzerland.
Dr. Doron Shmerling, CEO of PolyGene and research scientist Dr. Péter Horváth present our latest in-house research on inducible gene expression systems, as well as genetic modifications using CRISPR/Cas9 and similar technologies.
Get more information on our event calendar, we are looking forward meeting you soon.
We are pleased to inform you, that we continue our seminar series:
Join us for a special talk at the University of Bern, Thursday, April 27th at 1:15pm.
Please find more information here: Innovative Genetic Technologies in Transgenic Model Generation.
Join PolyGene for a special seminar on „Innovative Genetic Technologies in Transgenic Model Generation“. The event takes place April 19th 2017, 5pm, University of Zurich Y23 G04. The first talk will focus on CRISPR and transgenic rodent model services presented by Stephan Sonntag. In the second talk, Péter Horváth will give insight in state-of-the-art inducible gene expression systems and PolyGene’s in-house research. We are looking forward to meeting you there.
Lets start with a quote from Didier Picard from University of Geneva and Chair of the LS2 Annual Meeting 2017 in Zürich:
If you are a life scientist in Switzerland, this is the place to be and to be seen, at least once a year. Its dense program is designed to appeal to everyone, to give everyone the opportunity, again at least once a year, to get exposed to great science in their own field, but also to exciting and thought – provoking stuff from different fields or from the interfaces between science and the real world. The LS2 meeting is a great opportunity to network, to meet your old buddies from your undergraduate days, graduate school, and committees you have served on, your former professors, many of your suppliers, your current and future collaborators, and perhaps your future boss.
We had a great time there, meeting indeed old friends and customers but also created new bonds to possible future collaborations.
Our CEO Doron Shmerling has been an invited speaker within the Session “Start a start-up”. He brought his longlasting experience in managing a small enterprise to more than 150 students.
Connect with us at the LS2 Meeting at the University of Zurich 2nd-3th February, 2017.
LS2 is the annual meeting of Swiss experts in a broad range of life science disciplines.
Discover the latest, most exciting findings in the field, from Molecular and Cellular Biosciences to Proteomics and Physiology, or enjoy the Satellite Workshop on opportunities in academic and non-academic careers.
We invite our clients and researchers interested in transgenic animal model research to visit us at booth no.3!
Our CEO Doron Shmerling will also participate at an exciting panel discussion about starting a start-up. This event takes place Friday, 10:30 – 12:30 during the Parallel Symposia III.
More information can be found directly on the LS2 webpage: LS2 Annual Meeting
Wondering where you can meet PolyGene next? Check out our event calendar
Late December Offering:
Free genotyping and breeding of your new PolyGene mouse line (including CRISPR/Cas9 gene targeting, traditional ES cell targeting and pronuclear microinjection of your DNA), when ordering a complete mouse model!
- order before 30th December 2016.
- add the code “FreeGenotyping” in your quote.
Mid December Offering:
Get sperm freezing of your new mouse line for free, if you order a complete mouse model.
- order before 30th December 2016.
- add the code “FreeFreezing” in your quote.
Early December Offering:
Get free shipment of your next mouse model.
- order before 30th December 2016.
- add the code “FreeShipment” in your quote.
The offers mentioned above can not be combined.
Electrical heart disease leading to arrhythmias represents a major public health issue because it increases the risk for sudden cardiac death. The EUTrigTreat project investigates arrhythmia initiating mechanisms (Triggers) and addresses therapeutic strategies (Treatments) through translational and interdisciplinary strategies. The multidisciplinary research team of this large-scale collaborative excellence project set out to elucidate molecular and environmental mechanisms which underlie life-threatening cardiac arrhythmias, and how genes and external factors modulate and initiate catastrophic electrical abnormalities in the heart.
PolyGene’s role in EUTrigTreat was to generate more than 20 mouse models for various collaborating groups, and to build a cardiac-specific inducible knockout system to regulate one of those genes. All models were delivered in time to specification, in early phases of the project, to accommodate downstream research in our partner groups within the narrow time frame of EUTrigTreat. Official Webpage
The overall aim of CAM-PaC is to use a strongly SME-driven approach to contribute to solving the socioeconomic and health challenges of pancreatic ductal adenocarcinoma by an integrative and systematic functional analysis of pancreatic cancer candidate genes pre-selected and pre-characterised by members of the consortium in previous and ongoing HT-omics approaches.
CAM-PaC develops novel cellular and animal models for this aim, as well as novel strategies to analyse and integrate large scale metabolic, transcriptomic and genetic data. CAM-PaC systematically identifies, characterises and validates novel targets for therapeutic intervention and bioinfomatic models for predictive diagnostics.
PolyGene’s role is to supply these models (close to 20 novel mouse models), and on the other hand, to develop novel tools for gene expression regulation based on the antibiotic-driven expression systems currently already available at PolyGene, and patent protect them. Official Webpage